Israel - inglés - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israel - inglés - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israel - inglés - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Israel - inglés - Ministry of Health

eli lilly israel ltd, israel - insulin (human) - suspension for injection - insulin (human) 100 iu/ml - insulin (human) - insulin (human) - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Filipinas - inglés - FDA (Food And Drug Administration)

team excel distribution inc. - neutral insulin human , isophane human, recombinant dna - suspension, for sc injection - 100iu/ml(30%/70%)

Canadá - inglés - Health Canada

eli lilly canada inc - insulin; insulin isophane (nph) - suspension - 30unit; 70unit - insulin 30unit; insulin isophane (nph) 70unit - insulins

Estados Unidos - inglés - NLM (National Library of Medicine)

physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin r u-100 is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 1 and type 2 diabetes mellitus. humulin r u-100 may be administered intravenously under proper medical supervision in a clinical setting for glycemic control (see dosage and administration and storage). humulin r u-100 is contraindicated during episodes of hypoglycemia and in patients hypersensitive to humulin r u-100 or any of its excipients. never share needles and syringes. correct syringe type doses of insulin are measured in units . u-100 insulin contains 100 units/ml (1 ml=1 cc). with humulin r, it is important to use a syringe that is marked for u-100 insulin preparations. failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high. syringe use to help avoid contamination and possible infection, follow these instructions exactly. disposable syringes and needles should be used only

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general

Estados Unidos - inglés - NLM (National Library of Medicine)

a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is an intermediate-acting recombinant human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline a